Study of YK012 in B-cell Acute Lymphoblastic Leukemia

NCT06580301 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: YK012

Sponsor

Excyte Biopharma Ltd